These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 33812677)
1. Commentary: SGLT2 inhibitors reduce mortality and heart failure in patients with type 2 diabetes mellitus-is metabolic reprogramming the mechanism for these favorable outcomes? Lazar HL J Thorac Cardiovasc Surg; 2022 Sep; 164(3):901-904. PubMed ID: 33812677 [No Abstract] [Full Text] [Related]
2. SGLT2 Inhibitors in Type 2 Diabetes Mellitus. Ferrannini G; Savarese G; Cosentino F Heart Fail Clin; 2022 Oct; 18(4):551-559. PubMed ID: 36216485 [TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Garcia-Ropero A; Badimon JJ; Santos-Gallego CG Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454 [TBL] [Abstract][Full Text] [Related]
4. Use of SGLT2 Inhibitors in Patients With HF With and Without Type 2 Diabetes: An Endocrinologist's Perspective. Butler J; Pessah-Pollack R JACC Heart Fail; 2024 Jun; 12(6S):S4-S6. PubMed ID: 38839136 [TBL] [Abstract][Full Text] [Related]
6. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Packer M Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851 [TBL] [Abstract][Full Text] [Related]
7. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. Sano M J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819 [TBL] [Abstract][Full Text] [Related]
8. Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment. Packer M Am J Med; 2020 Jul; 133(7):781-782. PubMed ID: 32061625 [No Abstract] [Full Text] [Related]
9. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin. Avogaro A; Fadini GP Diabetes Obes Metab; 2018 Jun; 20(6):1367-1368. PubMed ID: 29377537 [No Abstract] [Full Text] [Related]
10. Dapagliflozin for heart failure: is it a class effect? Raj GM; Wyawahare M Future Cardiol; 2021 Mar; 17(2):355-361. PubMed ID: 32755319 [TBL] [Abstract][Full Text] [Related]
11. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes? Packer M Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741 [No Abstract] [Full Text] [Related]
12. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159 [TBL] [Abstract][Full Text] [Related]
13. The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug? Savarimuthu S; Harky A Expert Opin Pharmacother; 2022 Feb; 23(3):377-386. PubMed ID: 34713764 [TBL] [Abstract][Full Text] [Related]
14. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. Vaduganathan M; Januzzi JL Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436 [TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibitors in people with and without T2DM. Khunti K Nat Rev Endocrinol; 2021 Feb; 17(2):75-76. PubMed ID: 33293703 [No Abstract] [Full Text] [Related]